alexa Clinical Proof Of The Safety And Efficacy Of A New Method Delivering Ad5FGF-4 To Patients With Refractory Angina | 63839
ISSN: 2157-7633

Journal of Stem Cell Research & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

6th International Conference and Exhibition on Cell and Gene Therapy
March 27-28, 2017 Madrid, Spain

Gabor M Rubanyi
Angionetics Inc., USA
Posters & Accepted Abstracts: J Stem Cell Res Ther
DOI: 10.4172/2157-7633.C1.024
Abstract
One of the main hurdles of effective gene therapy is delivery of the product. We have developed a practical method of intracoronary artery infusion of Ad5 vector in pigs based on observations that both short term ischemia and nitric oxide augment Ad5 transfection in hearts. The new technique uses two consecutive transient (3 min) coronary artery occlusions by an inflatable balloon catheter combined with intracoronary infusion of nitroglycerin, which increased Ad5Luc expression in the pig heart by more than 100-fold. In order to prove the safety and efficacy of the new delivery method, we have initiated the ASPIRE clinical study. Eleven patients (7 who received a single intracoronary injection of 6x10e9 vp Ad5FGF-4 and 4 with standard of care) completed the study. None of treated patients showed any clinical signs of untoward effects due to the product delivery, and there was no elevation of blood troponin I levels. The treated patients showed a statistically significant (p<0.01) improvement in myocardial perfusion assessed by SPECT eight weeks after product administration. In conclusion, the new Ad5FGF-4 delivery method proved to be safe and well tolerated, and resulted in significant improvement in the primary efficacy endpoint in patients with refractory angina. This pilot study formed the basis for the start of a pivotal Phase III clinical trial in the US.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version